PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences: Piper Sandler Healthcare Conference, New York, NY: Fireside Chat on Tuesday, December 2 at 10:30 am ESTEvercoreISI HealthCONx Conference, Miami, FL: Fireside Chat on Wednesday, Decemb ...

Core Insights - MeiraGTx Holdings plc has announced a strategic collaboration with Eli Lilly in ophthalmology, focusing on the AAV-AIPL1 program for treating Leber congenital amaurosis 4 (LCA4) [1][2] Collaboration Details - MeiraGTx grants Lilly worldwide exclusive rights to the AAV-AIPL1 program, which has shown unprecedented clinical results, restoring vision in 11 legally blind children [2] - Lilly will also gain access to MeiraGTx's gene therapy technologies, including novel intravitreal capsids and AI-generated promoters for retinal applications [3] - The agreement includes an upfront payment of $75 million, with potential milestone payments exceeding $400 million, along with tiered royalties on licensed products [4] Company Background - MeiraGTx is a clinical-stage genetic medicines company with a comprehensive pipeline, including four late-stage clinical programs targeting inherited and common diseases [6] - The company has developed advanced manufacturing capabilities, with five global facilities, including two licensed for GMP viral vector production [6] - MeiraGTx's riboswitch technology allows precise control of gene expression through oral small molecules, applicable to various therapeutic areas [8]

Core Insights - Calidi Biotherapeutics, Inc. is hosting an investor event at the Society of Immunotherapy for Cancer (SITC) Annual Meeting to discuss its RedTail platform and lead candidate CLD-401 [1][2] - The company is conducting IND-enabling studies for CLD-401, targeting non-small cell lung cancer, head and neck cancer, and other high unmet medical need tumor types, with an IND application expected by the end of 2026 [2][4] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted genetic medicines using its proprietary RedTail platform, which utilizes an engineered enveloped oncolytic virus for systemic delivery to metastatic sites [3][4] - The RedTail platform aims to shield the virus from immune clearance, allowing effective virotherapy to reach tumor sites and deliver potent genetic medicines [3] Event Details - The investor presentation will take place on November 7 from 8:30 AM to 9:30 AM at the Gaylord National Hotel and Convention Center in National Harbor, Maryland, and will be live-streamed [2] - Key speakers at the event include Eric Poma, PhD, CEO of Calidi, and other experts from the Scientific Advisory Board [2][6]

Core Insights - BridgeBio Pharma reported a total revenue of $120.7 million for Q3 2025, driven primarily by $108.1 million in U.S. Attruby net product revenue, alongside $4.3 million from royalty revenue and $8.3 million in license and services revenue [1][3][10] - The company has seen significant commercial progress, with 5,259 unique patient prescriptions written by 1,355 unique prescribers as of October 25, 2025, indicating strong adoption of Attruby since its FDA approval in November 2024 [1][2][4] - BridgeBio plans to file New Drug Applications (NDAs) for BBP-418 and encaleret in the first half of 2026, aiming for full approval of these therapies [1][5][8] Commercial Performance - Attruby's launch has been characterized by strong physician adoption and continued growth across all market segments, reflecting its differentiated clinical profile [4][6] - The company reported a significant increase in total revenues, with a $118 million rise compared to the same period last year, primarily due to the commercial success of Attruby [10][11] Pipeline Developments - Positive interim analysis results from the FORTIFY Phase 3 study of BBP-418 showed a 1.8x increase in glycosylated αDG from baseline at 3 months, with sustained improvements at 12 months [1][8] - The CALIBRATE Phase 3 study of encaleret for ADH1 met its primary endpoint, with 76% of participants achieving target calcium levels at Week 24 [1][8] - The PROPEL 3 study of infigratinib for achondroplasia is fully enrolled, with topline results expected in early 2026 [1][8] Financial Overview - As of September 30, 2025, the company had $645.9 million in cash, cash equivalents, and marketable securities, positioning it well to support the commercialization of Attruby and advance its late-stage pipeline [1][9] - Operating costs for Q3 2025 were $265.9 million, reflecting increased investments in support of Attruby's commercial launch [14][15] Key Metrics - The net loss attributable to common stockholders for Q3 2025 was $182.7 million, compared to $162.0 million for the same period in the prior year, with a net loss per share of $0.95 [22][23] - Total revenues for the nine months ended September 30, 2025, were $347.9 million, up from $216.0 million in the prior year [11][12]

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following: Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results Webinar: Monday, October 27 at 8:00 am ETQ3 2025 Earnings: Wednesday, October 29 at 4:30 pm ET T ...

Core Viewpoint - Regeneron Pharmaceuticals, Inc. is set to report its third quarter 2025 financial and operating results on October 28, 2025, before the U.S. financial markets open [1] Group 1: Financial Reporting - The third quarter 2025 financial results will be announced before the market opens on October 28, 2025 [1] - A conference call and webcast will take place at 8:30 AM Eastern Time on the same day [1] Group 2: Conference Call Information - Participants can access the conference call live via webcast on Regeneron's 'Investors and Media' page [2] - Telephone participants must register in advance to receive a confirmation email with details on how to join the call [2] - A replay and transcript of the conference call will be available on the company's website for at least 30 days [2] Group 3: Company Overview - Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases [3] - The company is known for its ability to translate scientific research into approved treatments and has a robust pipeline of product candidates [3] - Regeneron's medicines target a wide range of conditions, including eye diseases, cancer, and rare diseases [3] Group 4: Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to develop optimized fully human antibodies and bispecific antibodies [4] - The company leverages data from the Regeneron Genetics Center to identify innovative treatment targets [4]

Core Insights - BridgeBio Pharma, Inc. is set to present significant findings related to its drug Acoramidis at the Heart Failure Society of America Annual Scientific Meeting 2025, highlighting its focus on genetic diseases [1][6]. Group 1: Clinical Presentations - A late-breaking clinical trial presentation will discuss the effect of Acoramidis on cardiovascular outcomes in patients with ATTR-CM, presented by Dr. Ahmad Masri on September 28 [2]. - An oral presentation will reveal that continuous treatment with Acoramidis significantly reduced the risk of all-cause mortality and cardiovascular-related hospitalization at month 42 for patients with transthyretin amyloidosis, presented by Dr. Lily Stern on September 27 [2]. Group 2: Poster Sessions - A poster session will present results showing that Acoramidis mitigates the rise in NT-proBNP levels compared to placebo in patients with variant transthyretin amyloid cardiomyopathy, presented by Dr. Nitasha Sarswat on September 27 [3]. - Another poster will discuss the effect of Acoramidis on cardiac conduction abnormalities in transthyretin amyloid cardiomyopathy, presented by Dr. Brett W. Sperry on September 27 [3]. - A poster will address state-level differences in the incidence of transthyretin amyloid cardiomyopathy among U.S. veterans after the introduction of disease-modifying therapy, presented by Dr. Sandesh Dev on September 28 [3]. Group 3: Product Information - Attruby™ (acoramidis) is indicated for treating cardiomyopathy associated with wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, aimed at reducing cardiovascular death and related hospitalizations [4]. Group 4: Safety Information - Adverse reactions reported for Attruby include diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation of the drug [5].

Core Viewpoint - Regeneron Pharmaceuticals, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 7:00 a.m. ET [1] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases [3] - The company was founded and is led by physician-scientists, emphasizing its ability to translate scientific research into approved treatments and product candidates [3] - Regeneron's medicines and pipeline target various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies, such as VelociSuite, to produce optimized fully human antibodies and new classes of bispecific antibodies [4] - The company is advancing drug development through data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms [4] - These innovations enable Regeneron to identify innovative targets and complementary approaches for potentially treating or curing diseases [4]

Core Insights - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing transformative medicines for genetic diseases [2] - The company will participate in several healthcare investor conferences, showcasing its commitment to engaging with investors [1][3] Company Overview - Founded in 2015, BridgeBio aims to discover, create, test, and deliver medicines for patients with genetic diseases [2] - The company's pipeline includes programs from early science to advanced clinical trials, indicating a robust development strategy [2] Upcoming Events - BridgeBio will host a fireside chat at the Wells Fargo Healthcare Conference on September 3 at 9:30 am ET [3] - The company will also participate in the Cantor Global Healthcare Conference on September 4 at 2:10 pm ET [3] - Additionally, a fireside chat is scheduled for the Morgan Stanley Global Healthcare Conference on September 8 at 3:20 pm ET [3]

Core Insights - Eli Lilly and Company has successfully completed the acquisition of Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease [1] - The acquisition is expected to transform treatment paradigms for millions of patients by providing lifelong cardiovascular risk reduction through a single treatment [2] Company Overview - Eli Lilly has been a pioneer in medical discoveries for nearly 150 years, helping tens of millions globally with its medicines [2] - The company is focused on addressing significant health challenges, including diabetes care, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [2] Strategic Implications - The integration of Verve Therapeutics is anticipated to enhance Lilly's capabilities in developing innovative genetic medicines for cardiometabolic diseases [2] - The acquisition aligns with Lilly's mission to make life better for millions by advancing clinical trials and ensuring medicine accessibility [2]